Skip to main content
Premium Trial:

Request an Annual Quote

Expression Analysis to be First US Service Provider for Pacific Bio Sequencing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Analysis today said that it will purchase one of Pacific Biosciences' single-molecule real-time DNA sequencers and become the first US service provider of the new technology.

Pacific Biosciences' RS DNA sequencing system is scheduled to be launched in the second half of 2010.

Durham, NC-based Expression Analysis said that the RS DNA sequencing system will enable it to better serve biotech and pharmaceutical firms, "specifically as it relates to oncology and infectious disease research."

The Menlo Park, Calif.-based firm a few months ago released the names of 10 institutions that had purchased its sequencing system as part of an early access program in North America. Expression Analysis was not among that group, which included the Baylor College of Medicine; the Broad Institute of MIT and Harvard; Cold Spring Harbor Laboratory; the US Department of Energy Joint Genome Institute; The Genome Center at Washington University; Monsanto; the National Cancer Institute/SAIC-Frederick; the National Center for Genome Resources; the Ontario Institute for Cancer Research; and Stanford University.

"The longer read lengths allow sequencing of complex regions of the genome never before possible and provide a more thorough understanding of structural genetic variations," Steve McPhail, president and CEO of Expression Analysis, said in a statement.

Among the other platforms Expression Analysis utilizes in its services are Affymetrix's GeneChip and GeneTitan, Applied Biosystems' Taqman, Illumina's BeadChip and Genome Analyzer, NanoString Technologies' nCounter Analysis System, and RainDance Technologies' RDT 1000.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.